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To the Editor:
Is early hepatocellular carcinoma (HCC) really a life-threatening
disease?
We would like to thank Dr. Francica for his interest in our
recently published article on the marginal survival beneﬁt of sur-
gery for early HCC [1]. Although our data did not refer to the
treatment for early HCC by radiofrequency ablation (RFA), we
had expected their proposal that early HCC patients are good can-
didates for RFA because of its low complication rate and high cur-
ability. Yet, we believe that their point of view is absolutely not
objective owing to the reasons described below.
First, the cirrhotic liver harboring early HCC is in quite a
highly carcinogenic state, and despite complete removal of early
HCCs, most of the patients have second primary HCCs, which
really need to be cured, as shown in Fig. 3B of our article [1]. In
addition to the long lead-time required for early HCC to become
overt HCC, it is not too late if early HCCs are resected or ablated
by RFA at the stage of ‘real’ HCC. Thus, early HCC is not a target
lesion for treatment, but a signaling lesion for a second primary
HCC.
Next, it cannot be determined whether early HCC (small hyp-
ovascular tumors) treated by RFA are actually HCC or not because
needle biopsy is not usually performed in patients who receive
RFA, as reported by Livraghi et al. [2], in their study, needle biopsy
was performed only in 18.3% of patients. This fact suggests that
good outcomes by RFA might be overestimated because of treat-
ment for precursor lesions of HCC. Actually, an apparently low
neoplastic-seeding rate by RFA in high-volume centers as
described above can be achieved by avoiding needle biopsy. We
therefore do not assume that good outcomes of RFA necessarily
lead to lower morbidity.
Finally, whether RFA for small HCCs is as effective as liver
resection also remains controversial because of the small num-
bers of patients enrolled in randomized controlled trials. One
randomized controlled trial performed by Feng et al. [3] sug-
gested that the outcomes of liver resection and RFA are not sig-
niﬁcantly different in patients with small HCCs. However, their
study group comprised only 168 patients. They concluded that
the result of percutaneous RFA depended on tumor location,
and recommended open or laparoscopic ‘surgery’. It is therefore
difﬁcult to standardize the use of RFA for the treatment of early
HCC. In addition, a Markov model analysis performed by Cho
et al. [4] revealed that overall survival after RFA was identical
to that after liver resection, provided that RFA was followed
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by liver resection in patients with initial local failure. On the
other hand, another randomized controlled trial in larger num-
bers of patients reported that liver resection was signiﬁcantly
more advantageous [5]. Thus, it cannot be simply concluded
that liver resection and RFA are of similar effectiveness for
the treatment of small HCC. To answer the question whether
liver resection is superior to RFA or not, a nationwide random-
ized controlled trial involving 600 patients is now ongoing in
Japan [6].
We should estimate treatment outcomes for early HCC from
the stand point of biological characteristics, which differ from
those of other types of cancers, including prostate cancer. Our
experience with patients with treated and untreated early HCC
suggests that early HCC pathologically deﬁnable as cancer might
clinically be a precancerous lesion. Therefore, the good outcomes
obtained by RFA for small HCCs that may include early HCC are
likely to be overestimated by lead-time bias.
Taken together, we advocate that early HCC is not a life-
threatening disease and, therefore, both liver resection and RFA
are unnecessary treatments for early HCC that cannot be justiﬁed,
regardless of minimal invasiveness or lower morbidity.
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Tuberculous sepsis during antiviral HCV triple therapy
To the Editor:
Drug users are a high-risk group for contracting infectious dis-
eases like tuberculosis (TB), HIV, hepatitis B (HBV), and hepatitis
C (HCV). The prevalence of latent tuberculosis infection in drug
users varies from 10% to 59%, and the prevalence of chronic
HCV infection in drug users ranges from 25% to 75% [1].
The standard of care for chronic HCV consists of pegylated
interferon (PegIFN), ribavirin, and boceprevir or telaprevir in
genotype (GT) 1 patients [2]. These drugs have complex immuno-
modulatory and antiproliferative effects, which can lead to alter-
ations in the cytokine cascade [3,4].
A 33-year-old white male former drug user and prison inmate
was willing to undergo antiviral treatment for HCV after jail
release. He participated in an opioid maintenance program and
had PCR-proven, treatment-naive, chronic hepatitis C infection,
genotype 1a, IL28B polymorphism CT. HBV and HIV co-infections
were excluded before starting therapy. Active pulmonary TB
infection was ruled out by a normal chest radiograph.
Antiviral HCV therapy started with PegIFN (180 lg/wk) and a
weight-based dose of ribavirin (1000 mg/d). Because the patient
did not achieve a rapid virological response, boceprevir (2.400
mg/d) was added at week 5. HCV RNA fell to undetectable levels
at week 8 and remained negative during subsequent evaluations.
During therapy, this patient developed grade IV anaemia, and
ribavirin was thus reduced and later completely stopped according
to labelling. In addition, erythropoietin and packed red blood cells
were administered, but the haemoglobin level fell to a low level of
5.9 mg/dl. Boceprevir was stopped at that time. During the total
course of therapy, the patient never developed neutropaenia, with
a neutrophilic count that never fell below 0.75 G/L. The patient did
not complain of fever or coughing. Details of the antiviral therapy
are shown in Fig. 1. Because the patient missed a regular control-
date appointment at week 21, another appointment was set for
four days later. He died one day after the appointment was set.
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Fig. 1. Course of haemoglobin, leucocytes, neutrophilic count (ANC) and viral
load (log10) during antiviral treatment. Administration of erythropoietin and
packed red blood cells is shown according to time.
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